Bone Metastasis - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 118 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Bone Metastasis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Bone Metastasis - Pipeline Review, H2 2014', provides an overview of the Bone Metastasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bone Metastasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Bone Metastasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bone Metastasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bone Metastasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bone Metastasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Bone Metastasis Overview 10
Therapeutics Development 11
Pipeline Products for Bone Metastasis - Overview 11
Pipeline Products for Bone Metastasis - Comparative Analysis 12
Bone Metastasis - Therapeutics under Development by Companies 13
Bone Metastasis - Therapeutics under Investigation by Universities/Institutes 16
Bone Metastasis - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Bone Metastasis - Products under Development by Companies 20
Bone Metastasis - Products under Investigation by Universities/Institutes 21
Bone Metastasis - Companies Involved in Therapeutics Development 22
Amgen Inc. 22
Eli Lilly and Company 23
Takeda Pharmaceutical Company Limited 24
Sigma-Tau S.p.A. 25
Bayer AG 26
Medivir AB 27
Osteologix Holdings Plc. 28
Transgene SA 29
Merrion Pharmaceuticals Plc 30
Digna Biotech, S.L. 31
Debiopharm International S.A. 32
Amura Holdings Ltd. 33
Alethia Biotherapeutics Inc. 34
Deciphera Pharmaceuticals, LLC 35
Terpenoid Therapeutics, Inc. 36
R-Pharm 37
TWi Pharmaceuticals, Inc. 38
DexTech Medical AB 39
AlphaMab Co., Ltd 40
Bone Metastasis - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Target 43
Assessment by Mechanism of Action 46
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
denosumab - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
zoledronic acid - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MLN-1202 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
radium Ra 223 dichloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Osteodex - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
MIV-711 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
RPH-203 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Debio-0719 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
P-17 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
disitertide - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
MIV-710 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
SST-0001 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
TG-3003 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
AB-25E9 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
AM-3701 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
DCC-2909 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
AC-301 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Vicrostatin - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
ADM-01 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
LY-2109761 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
LY-364937 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Drugs to Inhibit EGFR for Bone Metastasis - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
(alendronate sodium + paclitaxel + PEG) - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
alendronate sodium + HPMA + paclitaxel - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
DCC-3014 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Small Molecules to Inhibit GGDPS for Cancer and Bone Metastasis - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
TPH-9 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
NBS-101 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Recombinant Protein to Inhibit Serine Protease for Bone Metastasis - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
KN-013 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Bone Metastasis - Recent Pipeline Updates 92
Bone Metastasis - Dormant Projects 107
Bone Metastasis - Discontinued Products 108
Bone Metastasis - Product Development Milestones 109
Featured News & Press Releases 109
May 23, 2014: Daiichi Sankyo Receives Approval in Japan for Additional Indication Related to RANMARK for Treatment of Giant Cell Tumor of Bone 109
Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders 109
Oct 01, 2013: Goodwin Biotechnology Announces the Return of AB-25E9 Monoclonal Antibody Project from Alethia Biotherapeutics 110
Jul 17, 2013: The New England Journal of Medicine publishes results from the phase III ALSYMPCA study of Xofigo 111
Jun 20, 2013: Algeta Opens Commercial Production Facility For Xofigo Injection In Kjeller, Norway 112
May 30, 2013: Algeta Announces First Sale Of Xofigo In US 113
May 22, 2013: Celsion Receives Additional Patents Covering ThermoDox Technologies 114
Feb 15, 2013: Algeta Presents Further Sub-analysis Of Phase III ALSYMPCA Study Of Radium-223 Dichloride At 2013 Genitourinary Cancers Symposium 114
Jan 14, 2013: US Nuclear Regulatory Commission Issues Licensing Decision For Radium-223 Dichloride 115
Oct 23, 2012: Amgen's Xgeva Obtains Approval From NICE For Eligibility To NHS Funding 116
Appendix 117
Methodology 117
Coverage 117
Secondary Research 117
Primary Research 117
Expert Panel Validation 117
Contact Us 118
Disclaimer 118

List of Tables
Number of Products under Development for Bone Metastasis, H2 2014 11
Number of Products under Development for Bone Metastasis - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Products under Development by Companies, H2 2014 20
Products under Investigation by Universities/Institutes, H2 2014 21
Bone Metastasis - Pipeline by Amgen Inc., H2 2014 22
Bone Metastasis - Pipeline by Eli Lilly and Company, H2 2014 23
Bone Metastasis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 24
Bone Metastasis - Pipeline by Sigma-Tau S.p.A., H2 2014 25
Bone Metastasis - Pipeline by Bayer AG, H2 2014 26
Bone Metastasis - Pipeline by Medivir AB, H2 2014 27
Bone Metastasis - Pipeline by Osteologix Holdings Plc., H2 2014 28
Bone Metastasis - Pipeline by Transgene SA, H2 2014 29
Bone Metastasis - Pipeline by Merrion Pharmaceuticals Plc, H2 2014 30
Bone Metastasis - Pipeline by Digna Biotech, S.L., H2 2014 31
Bone Metastasis - Pipeline by Debiopharm International S.A., H2 2014 32
Bone Metastasis - Pipeline by Amura Holdings Ltd., H2 2014 33
Bone Metastasis - Pipeline by Alethia Biotherapeutics Inc., H2 2014 34
Bone Metastasis - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 35
Bone Metastasis - Pipeline by Terpenoid Therapeutics, Inc., H2 2014 36
Bone Metastasis - Pipeline by R-Pharm, H2 2014 37
Bone Metastasis - Pipeline by TWi Pharmaceuticals, Inc., H2 2014 38
Bone Metastasis - Pipeline by DexTech Medical AB, H2 2014 39
Bone Metastasis - Pipeline by AlphaMab Co., Ltd, H2 2014 40
Assessment by Monotherapy Products, H2 2014 41
Assessment by Combination Products, H2 2014 42
Number of Products by Stage and Target, H2 2014 45
Number of Products by Stage and Mechanism of Action, H2 2014 48
Number of Products by Stage and Route of Administration, H2 2014 50
Number of Products by Stage and Molecule Type, H2 2014 52
Bone Metastasis Therapeutics - Recent Pipeline Updates, H2 2014 92
Bone Metastasis - Dormant Projects, H2 2014 107
Bone Metastasis - Discontinued Products, H2 2014 108